
Opinion|Videos|July 5, 2024
Key Efficacy Data from PERSEUS in Newly Diagnosed Multiple Myeloma
Author(s)Cesar Rodriguez, MD, Frits van Rhee, MD, PhD
Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What are your initial impressions of the efficacy data from PERSEUS?
- What are the potential clinical implications of this data in your practice for TE NDMM patients?
- How might this data impact the current treatment landscape?
Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast Cancer
2
Who Benefits Most From Perioperative Therapy in High-Risk Prostate Cancer?
3
Belzutifan Plus Lenvatinib Earns Positive CHMP Opinion in Advanced ccRCC
4
Rocbrutinib Plus R-CHOP Yields High Complete Response Rate in Non-GCB DLBCL
5


